Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study

International Journal of Cardiology

Volumn 134, Issue 3, 2009, Pages 322-329

  Hatzitolios, A I ^a   Athyros, V G ^a   Karagiannis, A ^a   Savopoulos, C ^a   Charalambous, C ^b   Kyriakidis, G ^c   Milidis, Th ^d   Papathanakis, C ^e   Bitli, A ^f   Vogiatsis, I ^g   Ntaios, G ^a   Katsiki, N ^a   Symeonidis, A ^h   Tziomalos, K ⁱ   Mikhailidis, D P ⁱ  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Psychiatric Hospital   (Greece)

^c Agios Dimitrios Hospital   (Greece)

^d Serres Hospital   (Greece)

^e Health Centre of Orestiada   (Greece)

^f Kilkis Hospital   (Greece)

^g Veria Hospital   (Greece)

^h Health Centre of Paleohoriou   (Greece)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Best practice; Control; Dyslipidemia; Public health care; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CLOPIDOGREL; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG USE; DYSLIPIDEMIA; FEMALE; GOAL ATTAINMENT; HUMAN; HYPERTENSION; INFORMATION DISSEMINATION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MEDITERRANEAN DIET; MOTIVATION; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PILOT STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SECONDARY PREVENTION;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIET, MEDITERRANEAN; DISEASE MANAGEMENT; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 67349218137     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.02.001     Document Type: Article

References (34)

1. Kakafika A.I., Athyros V.G., Tziomalos K., Karagiannis A., and Mikhailidis D.P. Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother 9 (2008) 1437-1440
2. Ford E.S., Mokdad A.H., Giles W.H., and Mensah G.A. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 107 (2003) 2185-2189
3. Stanek E.J., Sarawate C., Willey V.J., Charland S.L., and Cziraky M.J. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 23 (2007) 553-563
4. Klingman D., Williams S.A., Benner J.S., Smith T.W., Ahn J., and O'Donnell J.C. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J 150 (2005) 595-601
5. MacDonald T.M., Morant S.V., and Mozaffari E. Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. J Hum Hypertens 21 (2007) 925-933
6. García Ruiz F.J., Marín Ibáñez A., Pérez-Jiménez F., et al. REALITY study group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY study. Pharmacoeconomics 22 Suppl 3 (2004) 1-12
7. van Wyk J.T., Picelli G., Dieleman J.P., et al. Management of hypertension and hypercholesterolaemia in primary care in the Netherlands. Curr Med Res Opin 21 (2005) 839-848
8. Athyros V.G., Elisaf M., and Mikhailidis D.P. Undertreatment of dyslipidaemia in Greece. Atherosclerosis 177 (2004) 215-216
9. Diamantopoulos E.J., Athyros V.G., Yfanti G.K., et al. OLYMPIC study group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) study. Angiology 56 (2005) 731-741
10. Kotseva K., Stagmo M., De Bacquer D., De Backer G., and Wood D. EUROASPIRE II study group. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 197 (2008) 710-717
11. Kindermann M., Adam O., Werner N., and Böhm M. Clinical trial updates (Wood DA) and hotline sessions presented at the European Society of Cardiology Congress 2007. Clin Res Cardiol 96 (2007) 767-786
12. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
13. Grundy S.M., Cleeman J.I., Merz C.N., et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
14. Sacks F.M. Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
15. UK HDL-C Consensus group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 20 (2004) 241-247
16. Expert committee on the diagnosis and the classification of diabetes mellitus. Report of the expert committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
17. Mancia G., De Backer G., Dominiczak A., et al. ESH-ESC Task force on the management of arterial hypertension. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
18. Fonarow G.C., Gawlinski A., Moughrabi S., and Tillisch J.H. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
19. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279 (1998) 1615-1622
20. Sever P.S., Dahlöf B., and Poulter N.R. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
21. Kostis J.B., Breazna A., Deedwania P.C., and LaRosa J.C. Treating to new targets steering committee and investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the treating to new targets (TNT) study. J Clin Hypertens (Greenwich) 10 (2008) 367-376
22. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek atorvastatin and coronary-heart disease evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
23. Jacobson T.A., Miller M., and Schaefer E.J. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther 29 (2007) 763-777
24. Athyros V.G., Kakafika A.I., and Papageorgiou A.A. GREACE study collaborative group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 42 (2007) 999-1009
25. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C., and European Consensus Panel on H.D.L.C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
26. Wierzbicki A.S., and Mikhailidis D.P. Beyond LDL-C-the importance of raising HDL-C. Curr Med Res Opin 18 (2002) 36-44
27. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. GREACE collaborative group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med Res Opin 20 (2004) 627-637
28. Kaplan R.C., Heckbert S.R., Furberg C.D., and Psaty B.M. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 55 (2002) 654-664
29. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Symeonidis A.N., Pehlivanidis A.N., Bouloukos V.I., and Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
30. Bickel C., Rupprecht H.J., Blankenberg S., et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 12-17
31. Athyros V.G., Elisaf M., and Papageorgiou A.A. GREACE study collaborative group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease. A subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis 43 (2004) 589-599
32. Trichopoulou A., Bamia C., Norat T., et al. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly study. Eur J Epidemiol 22 (2007) 871-881
33. Pitsavos C., Panagiotakos D.B., and Chrysohoou C. The Effect of the combination of Mediterranean diet and leisure time physical activity on the risk of developing acute coronary syndromes, in hypertensive subjects. J Hum Hypertens 16 (2002) 517-524
34. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150